As of May 23, 2025, BioCryst Pharmaceuticals Inc (BCRX) reports a ROE (Return on Equity) of -284.33%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of BioCryst Pharmaceuticals Inc's ROE (Return on Equity)
Over recent years, BioCryst Pharmaceuticals Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | -284.33% |
| 2023-12-31 | 49.73% |
| 2022-12-31 | 83.88% |
| 2021-12-31 | 172.06% |
| 2020-12-31 | 947.15% |
This gradual decrease highlights how BioCryst Pharmaceuticals Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing BioCryst Pharmaceuticals Inc's ROE (Return on Equity) to Peers
To better understand BioCryst Pharmaceuticals Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| BioCryst Pharmaceuticals Inc (BCRX) | -284.33% |
| Sorrento Therapeutics Inc (SRNE) | 3079.57% |
| Curis Inc (CRIS) | 723.39% |
| Humanigen Inc (HGEN) | 151.23% |
| Abbvie Inc (ABBV) | 128.66% |
| Amgen Inc (AMGN) | 69.59% |
Compared to its competitors, BioCryst Pharmaceuticals Inc's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.